Henriksson R, Franzén L, Littbrand B
Dept. of Oncology, University Hospital, Umeå, Sweden.
Scand J Gastroenterol Suppl. 1992;191:7-11. doi: 10.3109/00365529209093223.
In a double-blind randomized placebo-controlled study, including 70 patients treated with radiotherapy of localized malignancies in the pelvis, the effects of prophylactic sucralfate in preventing bowel discomfort were evaluated. Radiotherapy was delivered in a conventional manner with high-energy photons in a total dose of 62-66 Gy (target dose, 1.8-2.2 Gy) during 6.5 weeks. Dose granules of sucralfate or placebo were given 2 weeks after irradiation started and continued for 6 weeks. All analyses were performed blindly. The patients in the sucralfate group had significantly less problems with acute (5 weeks) and chronic (66 weeks) bowel discomfort. The consumption of loperamide was also reduced in the sucralfate group, and the weight decrease was less pronounced. No adverse effects were seen. Thus, sucralfate seems to be beneficial in minimizing the problems of bowel discomfort during and after irradiation of malignancies in the pelvis. These results are discussed in relation to other related observations.
在一项双盲随机安慰剂对照研究中，纳入了70例接受盆腔局部恶性肿瘤放射治疗的患者，评估了预防性使用硫糖铝预防肠道不适的效果。采用常规方式用高能光子进行放射治疗，总剂量为62 - 66 Gy（靶剂量1.8 - 2.2 Gy），疗程6.5周。在开始照射2周后给予硫糖铝或安慰剂的剂量颗粒，并持续6周。所有分析均在盲态下进行。硫糖铝组患者在急性（5周）和慢性（66周）肠道不适方面的问题明显较少。硫糖铝组洛哌丁胺的消耗量也有所减少，体重下降也不那么明显。未观察到不良反应。因此，硫糖铝似乎有利于减轻盆腔恶性肿瘤放疗期间及放疗后肠道不适的问题。结合其他相关观察结果对这些结果进行了讨论。
